Skip to main content
. 2005 May 10;106(4):1341–1345. doi: 10.1182/blood-2004-11-4477

Table 1.

Sample characteristics

Patient Isotype Level of IgM in patient, mg/dL Biopsy, % bone marrow infiltration Prior therapy Cells inoculated, × 106 Weeks to detection of IgM Level of IgM in mouse,*μg/mL Level of light chain in mouse,*μg/mL
1 IgM κ 1240 90 RTX, THAL 5 4 1.8 Negative
2 IgM κ 6130 60 Prednisone 5 16 10 Negative
3 IgM κ 4830 50 Fl, RTX 5 6 0.6 NA
4 IgM κ 1430 70 THAL, DEX 5 28 2.6 0.7
5 IgM λ 2590 60 RTX 10 4 1.5 Negative
6 IgM κ 2390 70-80 None 10 5 2.6 NA
7 IgM, κ 7630 90 None 2 13 0.4 NA
8 IgM,κ NA NA None 2 20 0.2 0.4
9 IgM κ 4970 95 CVP, RTX 2 7 8.4 0.4
10 IgM,κ 2340 50 None 2 20 1.8 NA

RTX indicates rituximab; THAL, thalidomide; Fl, fludarabine; NA, not available; DEX, dexamethasone; CVP, cyclophosphamide, vincristine, and prednisone.

*

At time of first IgM detection.

In these cases, BM cells were CD19-immunomagnetically sorted before mice inoculation into human bone implant.